智通财经APP获悉，今海医疗科技(02225)涨近8%，截至发稿，涨6.25%，报1.36港元，成交额293.64万港元。
公开资料显示，今海医疗专注于微创手术的整体医疗产品解决方案，打造研发、生产、销售和服务的全产业链闭环。产品涵盖4K超高清内窥镜系统、3D及裸眼3D图像处理系统、4K荧光及多光谱超高清内窥镜系统、8K内窥镜系统及相关辅助设备。今海医疗凭借“4K3D裸眼荧光内窥镜摄像系统”荣获“器械之家2025年十大内镜创新产品”称号。
值得注意的是，今海医疗科技于今年1月初发布公告称，其下属子公司今海协寰医疗授权国药菱商为公司高端医疗器械在中国的独家分销商。此次签约合作商业的产品基本上涵盖了今海医疗一篮子拳头产品，包括如4K3D荧光复合内窥镜、椎间孔镜以及一系列先进的器械套装等。公开资料显示，国药菱商隶属于中国医药集团总公司旗下，由国药控股股份有限公司和日本三菱商事共同合资的子公司。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.